



Next-Generation Beneficial Microbes: The Case of *Akkermansia muciniphila*

Patrice D. Cani^{1*} and Willem M. de Vos^{2,3}

¹ Walloon Excellence in Life Sciences and BIOTechnology, Metabolism and Nutrition Research Group, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium, ² Laboratory of Microbiology, Wageningen University, Wageningen, Netherlands, ³ Immunobiology Research Program, Research Programs Unit, Department of Bacteriology and Immunology, University of Helsinki, Helsinki, Finland

OPEN ACCESS

Edited by:

Rebeca Martín,
INRA Centre Jouy-en-Josas, France

Reviewed by:

Muriel Derrien,
Danone, France
Nuria Salazar,
Instituto de Productos Lácteos
de Asturias (IPLA-CSIC), Spain

*Correspondence:

Patrice D. Cani
patrice.cani@uclouvain.be

Specialty section:

This article was submitted to
Food Microbiology,
a section of the journal
Frontiers in Microbiology

Received: 03 July 2017

Accepted: 31 August 2017

Published: xx September 2017

Citation:

Cani PD and de Vos WM (2017)
Next-Generation Beneficial Microbes:
The Case of *Akkermansia muciniphila*.
Front. Microbiol. 8:1765.
doi: 10.3389/fmicb.2017.01765

Metabolic disorders associated with obesity and cardiometabolic disorders are worldwide epidemic. Among the different environmental factors, the gut microbiota is now considered as a key player interfering with energy metabolism and host susceptibility to several non-communicable diseases. Among the next-generation beneficial microbes that have been identified, *Akkermansia muciniphila* is a promising candidate. Indeed, *A. muciniphila* is inversely associated with obesity, diabetes, cardiometabolic diseases and low-grade inflammation. Besides the numerous correlations observed, a large body of evidence has demonstrated the causal beneficial impact of this bacterium in a variety of preclinical models. Translating these exciting observations to human would be the next logic step and it now appears that several obstacles that would prevent the use of *A. muciniphila* administration in humans have been overcome. Moreover, several lines of evidence indicate that pasteurization of *A. muciniphila* not only increases its stability but more importantly increases its efficacy. This strongly positions *A. muciniphila* in the forefront of next-generation candidates for developing novel food or pharma supplements with beneficial effects. Finally, a specific protein present on the outer membrane of *A. muciniphila*, termed Amuc_1100, could be strong candidate for future drug development. In conclusion, as plants and its related knowledge, known as pharmacognosy, have been the source for designing drugs over the last century, we propose that microbes and microbiomegnosy, or knowledge of our gut microbiome, can become a novel source of future therapies.

Keywords: *Akkermansia muciniphila*, obesity, diabetes mellitus, type 2, probiotics and prebiotics, gut barrier function

INTRODUCTION

Overweight and obesity have reached epidemic proportions with more than 600 million of adults and 100 million children of the world's population suffering from obesity (GBD 2015 Obesity Collaborators et al., 2017). Obesity predisposes to the development of type 2 diabetes and cardiovascular diseases. These two pathologies are part of the metabolic syndrome that is also becoming major problem in public health (Abdelaal et al., 2017; Ajala et al., 2017). Gut microbes play an important role in the regulation of host metabolism and low-grade inflammation

(Hartstra et al., 2015; Marchesi et al., 2016; Cani, 2017). The perturbation of the composition and the activity of the gut microbiota, also known as dysbiosis, is thought to be involved in the emergence of the metabolic syndrome (Wen and Duffy, 2017). Nowadays, numerous studies have demonstrated that our dietary habits strongly influence the composition and function of the gut microbiota and eventually may contribute to the onset or the protection against metabolic disorders (David et al., 2014; Korpela et al., 2014; Salonen et al., 2014; Carmody et al., 2015; Zeevi et al., 2015; Cani and Everard, 2016; Thaiss et al., 2016).

Well documented among the potential ways to affect the gut microbiota, is the consumption of selected microbes that are marketed as probiotics defined as “live microorganisms that when administered in adequate amounts confer a health benefit on the host” (Hill et al., 2014). It is worth noting that the current majority of probiotics sold on the market include mainly microorganisms from the genera *Lactobacillus* and *Bifidobacterium* (Douillard and de Vos, 2014). However, other ways such as the consumption of prebiotics have gained considerable attention over the last 20 years (Roberfroid et al., 2010). The prebiotic concept, discovered in Gibson and Roberfroid (1995), has led to a great number of dietary supplements that is an important growth market. The definition of prebiotic is now widely used and has been recently revised as “a substrate that is selectively utilized by host microorganisms conferring a health benefit” (Gibson et al., 2017). Thus, nutritional components that escape the digestion in the upper alimentary tract may have an impact on the gut microbiota by modulating some members of the gut microbiota its composition and its activity. However, the concept of prebiotic has not yet revealed all its secrets. In spite of numerous discoveries of molecular mechanisms explaining how prebiotics and the gut microbiota interact with the host, it remains difficult to identify the bacterial candidate(s) involved in the beneficial effects observed on the energy, glucose, lipid metabolism and immunity.


FROM PREBIOTIC TO NEXT-GENERATION PROBIOTIC: FOCUS ON THE IDENTIFICATION OF *Akkermansia muciniphila*

Akkermansia muciniphila is one of the most abundant single species in the human intestinal microbiota (0.5–5% of the total bacteria) and has been isolated and characterized as a mucin-utilizing specialist in 2004 by Muriel Derrien in her Ph.D. research at Wageningen University (Derrien et al., 2004; Collado et al., 2007). This discovery was initiated by the notion that the human body produces its own “prebiotics” or microbial substrates, namely mucus, an abundant glycoprotein that is specifically produced and degraded in the colon (Ouweland et al., 2005). While germ-free mouse experiments showed that *A. muciniphila* showed immune and metabolic signaling, specifically in the colon, the exact functions of this unusual microbe remained enigmatic (Derrien et al., 2008, 2011).

Further indications for the function of *A. muciniphila* were subsequently determined in other prebiotic studies using inulin-type fructans that were initially characterized as bifidogenic compounds able to increase the abundance of *Bifidobacterium* spp. (Gibson and Roberfroid, 1995). Thanks to the development of novel culture-independent techniques, we decided to revise in depth the impact of such kind of prebiotics on the overall microbial community in mice. Therefore, in search of potential novel bacterial candidates, we combined different techniques (phylogenetic microarray, high-throughput sequencing, gradient denaturation gel and qPCR), which allowed us to analyze and to compare all the bacteria that were present in the intestinal microbiota. The first surprise was to discover that more than 100 different taxa were affected by prebiotics (Figure 1) (Everard et al., 2011; Everard et al., 2014). Among these bacteria, we found that the relative abundance of *A. muciniphila* increased more than 100-fold following the ingestion of prebiotics thereby reaching the abundance of up to 4.5% under high-fat diet (Everard et al., 2014), whereas this effect was lower under normal chow diet (0.09–2.5%) depending on the model (Everard et al., 2011, 2014). It is worth noting that these findings are confirmed in different set of experiments (Everard et al., 2013; Liu et al., 2016; Reid et al., 2016; Catry et al., 2017; Zhu et al., 2017). Interestingly, we and others discovered that *A. muciniphila* was less abundant in the intestinal microbiota of both genetic and diet-induced obese and diabetic mice (Everard et al., 2011, 2013, 2014; Schneeberger et al., 2015; Leal-Diaz et al., 2016; Ojo et al., 2016; Song et al., 2016; Singh et al., 2017), however, few studies reported in mice an increased abundance of *A. muciniphila* upon the ingestion of a high-fat high sucrose diet (Anhe et al., 2015; Carmody et al., 2015). It has also been largely demonstrated that inulin-type fructans feeding improves metabolic disorders associated with obesity, including a decreased fat mass, insulin resistance, lower liver steatosis and a reinforcement of the gut barrier (Figure 1) (Cani et al., 2004, 2006, 2009; Maurer et al., 2010; Everard et al., 2011; Pachikian et al., 2012; Greer et al., 2016). Importantly, in humans the abundance of *A. muciniphila* was decreased in several pathological situations such as obesity, type 2 diabetes, inflammatory bowel diseases, hypertension and liver diseases (Png et al., 2010; Belzer and de Vos, 2012; Zhang et al., 2013; Dao et al., 2015; Yassour et al., 2016; Grandjean et al., 2017; Li et al., 2017). Conversely, antidiabetic treatments, such as metformin administration and bariatric surgery were both found to be associated with a marked increase in the abundance of *A. muciniphila* (Figure 1) (Shin et al., 2014; Forslund et al., 2015; de la Cuesta-Zuluaga et al., 2017). Therefore, a large body of evidence suggested that *A. muciniphila* may contribute to protect from specific metabolic disorders and cardiometabolic risk factors associated with a low-grade inflammatory tone.

ADMINISTRATION OF *Akkermansia muciniphila*: MULTIPLE EFFECTS ON THE GUT AND BEYOND

Inspired by the numerous indications that the relative levels of *A. muciniphila* decreased during obesity and metabolic disorders



in mouse and man, we decided to study the causal link between *A. muciniphila* and improvements in metabolism. This was done by investigating the impact of a daily oral supplementation with live *A. muciniphila* on the onset of obesity, diabetes and gut barrier dysfunction in mice. We found that the administration of live *A. muciniphila* at the dose of 2.10^8 bacterial cells per day was partly protecting against diet-induced obesity in mice (Everard et al., 2013). Indeed, mice showed a 50% lower body weight gain when treated with live *A. muciniphila* without altering neither their dietary food intake nor the elimination of dietary fats in fecal matter. This protection was mirrored by two times less visceral and subcutaneous fat mass (Figure 1), but also

by increased markers of fatty acid oxidation in the adipose tissue (Everard et al., 2013). In addition, animals receiving live *A. muciniphila* did no longer exhibited insulin resistance, nor infiltration of inflammatory cells (CD11c) in the adipose tissue, which is a key characteristic of obesity and associated low-grade inflammation (Everard et al., 2013). Interestingly, most of all the metabolic improvements observed following treatment with live *A. muciniphila* were in the range as those observed following oligofructose or inulin treatment (Cani et al., 2009; Dewulf et al., 2011; Everard et al., 2011, 2014), although live *A. muciniphila* was not affecting food intake behavior as do prebiotics like inulin and oligofructose.

343 Knowing that these metabolic features can be caused by
 344 an increased plasma LPS level (i.e., metabolic endotoxemia)
 345 or bacterial translocation (Cani et al., 2007; Amar et al.,
 346 2011), we next investigated the gut barrier function by
 347 measuring several markers. We observed that live *A. muciniphila*
 348 prevented the development of metabolic endotoxemia, an effect
 349 associated with the restoration of a normal mucus layer
 350 thickness (**Figure 1**) (Everard et al., 2013). We also found that
 351 administration of live *A. muciniphila* restored the endogenous
 352 production of antimicrobial peptides. We then discovered that
 353 live *A. muciniphila* increased the endogenous production of
 354 specific bioactive lipids that belongs to the endocannabinoid
 355 family and are known to have anti-inflammatory activities
 356 and regulating the endogenous production of gut peptides
 357 involved in glucose regulation and gut barrier, respectively,
 358 glucagon-like peptide-1 and 2 (GLP-1 and GLP-2) (Cani
 359 et al., 2016). It is worth noting that all these findings have
 360 subsequently been confirmed by different groups and extended
 361 to other specific disorders such as atherosclerosis, hepatic
 362 inflammation and hypercholesterolemia (Shin et al., 2014; Li
 363 et al., 2016; Shen et al., 2016; Grander et al., 2017; Plovier et al.,
 364 2017).

365 Collectively all these data reinforce the assumption that
 366 live *A. muciniphila* can be considered as a next-generation
 367 beneficial microbe with the exceptional particularity that this
 368 bacterium can act on numerous facets of the metabolic syndrome
 369 and cardiometabolic disorders. Still, these discoveries have
 370 raised different fundamental questions that will still have to be
 371 studied in humans with the aim to generate new therapeutic
 372 tools.

374 CROSSING THE BARRIER OF SPECIES: 375 FROM MICE TO MAN 376 377

378 *Akkermansia muciniphila* requires specific culture conditions
 379 and complex animal-based medium (i.e., mucin from animal
 380 source) and although it may respire under microaerophilic
 381 conditions, the cells are relatively sensitive to oxygen
 382 (Ouwkerk et al., 2016). These properties complicate the
 383 administration of *A. muciniphila* to human as to evaluate
 384 its potential, hence limiting its therapeutic perspectives.
 385 In order to solve this problem, a synthetic medium was
 386 developed in order to allow the culture of *A. muciniphila*
 387 with a high yield and devoid of compounds incompatible
 388 with administration in humans (Plovier et al., 2017; Van
 389 der Ark et al., unpublished data). Besides the successful
 390 development of this synthetic medium, the previous
 391 assessment of the efficacy of *A. muciniphila* were performed
 392 with cells grown on a mucin-based medium. Therefore,
 393 the bacteria cultured on the different media were tested
 394 and compared. Interestingly, *A. muciniphila* retains its
 395 effectiveness independently of the medium used, and as
 396 previously observed, mice treated with the bacterium gained less
 397 weight, exhibited an improved glucose tolerance, and insulin
 398 resistance under hyperlipidic diet (**Figure 1**) (Plovier et al.,
 399 2017).

400 SERENDIPITY: THE UNEXPECTED 401 ADVANTAGE OF PASTEURIZATION 402

403 In 2013, it was showed that the protective effects of *A. muciniphila*
 404 disappeared when the bacterium was destroyed by using
 405 autoclaving, a heat treatment that destroys all the constituents
 406 of bacteria and spores (Everard et al., 2013). As *A. muciniphila*
 407 is a Gram-negative bacterium and hence no spore-former, we
 408 were interested what the effects would be of pasteurization, a
 409 milder heat inactivation method than autoclaving. Therefore, we
 410 tested the impact of administrating pasteurized *A. muciniphila*
 411 (30 min at 70°C) cells on diet-induced metabolic disorders
 412 in mice. Unexpectedly, this method of inactivation did not
 413 abolish the effect of *A. muciniphila* but even exacerbated its
 414 beneficial impact. Specifically, mice receiving the pasteurized
 415 bacterium and the high-fat diet had a similar body weight
 416 gain and fat mass than those observed in mice fed a control
 417 diet. Again, these effects were independent of the food intake
 418 but pasteurized *A. muciniphila* increased the loss of energy in
 419 the feces of the treated mice, indicating a decrease in energy
 420 absorption that could contribute to explain the lower weight
 421 gain. Pasteurized *A. muciniphila* also strongly improved glucose
 422 tolerance, hepatic insulin sensitivity, and completely blocked the
 423 diet-induced metabolic endotoxemia. Although, the mechanisms
 424 of action of the bacteria are not yet fully elucidated, it is known
 425 that *A. muciniphila* express numerous highly abundant protein
 426 on its outer membrane (Ottman et al., 2017). Among these
 427 proteins, Amuc_1100, implicated in the formation of pili by
 428 *A. muciniphila*, was one of the most abundant (Plovier et al.,
 429 2017).

432 *Akkermansia muciniphila*: A GATE 433 KEEPER THAT DIALOGS WITH THE 434 INNATE IMMUNE SYSTEM 435

436 We previously found that *A. muciniphila* was able to restore
 437 the expression of specific antimicrobial peptides (Everard et al.,
 438 2013). However, Nucleotide oligomerization domain (NOD)-
 439 like receptors (NLRs) and Toll-Like Receptors (TLRs) are a
 440 specialized group of membrane and intracellular proteins that
 441 play a critical role in the regulation of immunity and are
 442 directly involved in the recognition of bacterial constituents by
 443 the immune system. Therefore, we evaluated the potential of
 444 *A. muciniphila* to activate different NOD and TLRs. Strikingly,
 445 we found that the bacteria specifically interact with TLR2.
 446 TLR2 has been shown to modulate intestinal homeostasis and
 447 host metabolism (Caricilli et al., 2011; Brun et al., 2013),
 448 thereby participating in the interactions between microbes and
 449 host. In addition, to better characterize the interaction between
 450 *A. muciniphila* and this receptor, we took advantage of genomic
 451 and proteomic analyzes of the external membrane of the
 452 bacterium, which may be exposed to host receptors (Ottman
 453 et al., 2016). Among these proteins, Amuc_1100 was one of the
 454 most abundant. This protein is implicated in the formation of pili
 455 by *A. muciniphila* and thus could participate in the interaction
 456

between the bacterium and TLR2. This hypothesis was further confirmed by showing that a version of the genetically engineered protein (called Amuc_1100*) was effectively activating TLR2 and with the same magnitude as *A. muciniphila*. In addition, Amuc_1100* remained stable at the temperature used during pasteurization, and could therefore contribute to the effects of the pasteurized bacterium. Amuc_1100* was also able to replicate almost all the effects of *A. muciniphila* alive or pasteurized in high-fat diet fed mice. *A. muciniphila*, whether live or pasteurized, and Amuc_1100* also decreased high cholesterol levels induced by the high-fat diet. Conversely, the pasteurized bacterium specifically also reduced the triglyceridemia of the treated mice, reinforcing the idea that the pasteurization of *A. muciniphila* reinforces its protective effects. A potential mechanism explaining this could be the exposure of active molecules by the heat treatments, including Amuc_1100, or the inactivation of inhibitory compounds, or combinations thereof.

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

FIRST ASSESSMENT OF *A. muciniphila* IN HUMANS WITH METABOLIC SYNDROME

As discussed earlier, *A. muciniphila* has various advantages as compared to other beneficial microbes and specific probiotics, at least in the context of the metabolic syndrome. *A. muciniphila* is present in the human milk, is highly abundant in lean and non-diabetic subjects, and is even highly increased upon metformin treatment of gastric bypass surgery, and this without obvious deleterious impact. This unique character does not preclude the fact the human investigations and safety assessment must be done. Hence, to become a putative future food supplement, the safety must be tested. We evaluated the toxicity and the emergence of possible side effects related to the administration of *A. muciniphila* in humans (20 subjects) as part of an ongoing clinical trial of individuals with metabolic syndrome (Plovier et al., 2017). To this end, we analyzed relevant clinical parameters related to liver, muscles and renal functions as well as markers of immunity and inflammation in individuals who received *A. muciniphila* daily for 2 weeks and then extended to 3 months. Whatever the formulation of *A. muciniphila* (live at 10^9 and 10^{10} bacteria per day or pasteurized at 10^{10} bacteria per day), no changes were observed for the markers tested after 2 weeks or 3 months of daily administration. In addition, the frequency of side effects reported by patients were similar in the different groups. These first data indicate that *A. muciniphila* (active or pasteurized) is tolerated in individuals with metabolic syndrome and is likely not toxic.

While *A. muciniphila* is one of the handful of core microbes identified in the intestinal microbiota of over 1000 human adults (Shetty et al., 2017), the administration of its cells, either in live or pasteurized form, in a dietary supplement may be subject to regulatory frameworks that aim to safeguard the consumer. The regulatory requirements relating to the use of live *A. muciniphila* have recently been addressed (Gomez-Gallego et al., 2016). This review summarized the recent comprehensive studies related to *A. muciniphila* and its safety properties and provided criteria

to be addressed when *A. muciniphila* cells are to be considered as a novel food by the European Food Safety Authority in Europe. One aspect that is relevant here and applies to other core intestinal microbes as well, is the fact that most if not all healthy subjects carry these anaerobes. So these have to be consumed at some stage and in this context it is important to note that *A. muciniphila* is present in early life microbiota and has been detected in mothers' milk (Collado et al., 2007, 2012; Derrien et al., 2008; Jeurink et al., 2013; Ward et al., 2013). Another aspect relates to the antibiotic resistance of *A. muciniphila* that has been studied to some extent in healthy human subjects that carried high levels of *A. muciniphila*-like bacteria and apparently were sensitive to penicillin and tetracycline derivatives but resistant to vancomycin (Dubourg et al., 2013). This was confirmed in *in vitro* studies on the antibiotic resistance profile with the type strain Amuc^T (Ouwkerk Ph.D. Thesis Wageningen University 2016). Moreover, inspection of the genome sequence did not reveal antibiotic resistance genes that are linked to known genetically transferrable elements (Gomez-Gallego et al., 2016).

CONCLUSION

Since its discovery in 2004, numerous studies have mostly linked the abundance of *A. muciniphila* with beneficial effects, and this although very few exceptions exist in specific non-physiological models (i.e., gnotobiotic models, specific immune double knock-out models) (Seregin et al., 2017).

Nowadays, *A. muciniphila* is widely considered as a novel potential candidate to improve metabolic disorders associated with obesity, diabetes, liver diseases and cardiometabolic disorders. Indeed, its administration has been shown to profoundly reduce the development of such diseases.

Other important steps toward the development of *A. muciniphila* as a next-generation beneficial microbe have been successfully reached. First, the discovery that *A. muciniphila* remained effective by being grown on a synthetic medium compatible with administration in humans. Second, the discovery that inactivation of the bacteria by pasteurization improved its effects, and thus its stability and potential shelf life. Third, the identification of a key mechanisms of interaction between *A. muciniphila* and its host via the identification of Amuc_1100, and last but not least; fourth, the demonstration that *A. muciniphila* may be safely administered in the human targeted population.

Finally, the pasteurized bacteria and the identification and the isolation of bacterial constituents such as the relatively small 30-kDa Amuc_1100 open the door to putative development of drugs based on *A. muciniphila*-related product that could also target pathologies such as type 1 diabetes, inflammatory bowel diseases or diseases where the intestinal barrier function is compromised.

AUTHOR CONTRIBUTIONS

PC and WdV: Conceptualized the review content.

FUNDING

PC is senior research associates at FRS-FNRS (Fonds de la Recherche Scientifique). PC is recipient of grants from FNRS (Project de Recherche, convention: T.0138.14) and Walloon region DG06-FSO project (Microbes 1510053). This work was supported by the FRFS-WELBIO under grant: WELBIO-CR-2012S-02R. This work is supported in part by the Funds Baillet Latour (Grant for Medical Research 2015). PC is a recipient of POC ERC grant 2016 (European Research Council, Microbes4U_713547) and ERC Starting Grant 2013 (Starting grant 336452-ENIGMO). WdV is partially supported

REFERENCES

- Abdelaal, M., le Roux, C. W., and Docherty, N. G. (2017). Morbidity and mortality associated with obesity. *Ann. Transl. Med.* 5:161. doi: 10.21037/atm.2017.03.107
- Ajala, O., Mold, F., Boughton, C., Cooke, D., and Whyte, M. (2017). Childhood predictors of cardiovascular disease in adulthood. A systematic review and meta-analysis. *Obes. Rev.* 18, 1061–1070. doi: 10.1111/obr.12561
- Amar, J., Chabo, C., Waget, A., Klopp, P., Vachoux, C., Bermudez-Humaran, L. G., et al. (2011). Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. *EMBO Mol. Med.* 3, 559–572. doi: 10.1002/emmm.201100159
- Anhe, F. F., Roy, D., Pilon, G., Dudonne, S., Matamoros, S., Varin, T. V., et al. (2015). A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice. *Gut* 64, 872–883. doi: 10.1136/gutjnl-2014-307142
- Belzer, C., and de Vos, W. M. (2012). Microbes inside—from diversity to function: the case of Akkermansia. *ISME J.* 6, 1449–1458. doi: 10.1038/ismej.2012.6
- Brun, P., Giron, M. C., Qesari, M., Porzionato, A., Caputi, V., Zoppellaro, C., et al. (2013). Toll-like receptor 2 regulates intestinal inflammation by controlling integrity of the enteric nervous system. *Gastroenterology* 145, 1323–1333. doi: 10.1053/j.gastro.2013.08.047
- Cani, P. D. (2017). Gut microbiota - at the intersection of everything? *Nat. Rev. Gastroenterol. Hepatol.* 14, 321–322. doi: 10.1038/nrgastro.2017.54
- Cani, P. D., Amar, J., Iglesias, M. A., Poggi, M., Knauf, C., Bastelica, D., et al. (2007). Metabolic endotoxemia initiates obesity and insulin resistance. *Diabetes Metab. Res. Rev.* 56, 1761–1772. doi: 10.2337/db06-1491
- Cani, P. D., Dewever, C., and Delzenne, N. M. (2004). Inulin-type fructans modulate gastrointestinal peptides involved in appetite regulation (glucagon-like peptide-1 and ghrelin) in rats. *Br. J. Nutr.* 92, 521–526. doi: 10.1079/BJN20041225
- Cani, P. D., and Everard, A. (2016). Talking microbes: when gut bacteria interact with diet and host organs. *Mol. Nutr. Food Res.* 60, 58–66. doi: 10.1002/mnfr.201500406
- Cani, P. D., Knauf, C., Iglesias, M. A., Drucker, D. J., Delzenne, N. M., and Burcelin, R. (2006). Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like peptide 1 receptor. *Diabetes Metab. Res. Rev.* 55, 1484–1490. doi: 10.2337/db05-1360
- Cani, P. D., Plovier, H., Van Hul, M., Geurts, L., Delzenne, N. M., Druart, C., et al. (2016). Endocannabinoids - at the crossroads between the gut microbiota and host metabolism. *Nat. Rev. Endocrinol.* 12, 133–143. doi: 10.1038/nrendo.2015.211
- Cani, P. D., Possemiers, S., Van de, W. T., Guiot, Y., Everard, A., Rottier, O., et al. (2009). Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. *Gut* 58, 1091–1103. doi: 10.1136/gut.2008.165886
- Caricilli, A. M., Picardi, P. K., de Abreu, L. L., Ueno, M., Prada, P. O., Ropelle, E. R., et al. (2011). Gut microbiota is a key modulator of insulin resistance in TLR 2 knockout mice. *PLoS Biol.* 9:e1001212. doi: 10.1371/journal.pbio.1001212

by ERC Advanced Grant 250172 (Microbes Inside), the SIAM Gravity Grant 024.002.002 and Spinoza Award of the Netherlands Organization for Scientific Research, and Grants 137389, 141140 and 1272870 of the Academy of Finland.

ACKNOWLEDGMENTS

We thank all the collaborators who have contributed to 10 years of Akkermansia discoveries, Dr. M. Derrien, Dr. C. Belzer, Dr. A. Everard, and Dr. H. Plovier.

- Carmody, R. N., Gerber, G. K., Luevano, JM Jr, Gatti, D. M., Somes, L., Svenson, K. L., et al. (2015). Diet dominates host genotype in shaping the murine gut microbiota. *Cell Host Microbe* 17, 72–84. doi: 10.1016/j.chom.2014.11.010
- Catry, E., Bindels, L. B., Tailleux, A., Lestavel, S., Neyrinck, A. M., Goossens, J. F., et al. (2017). Targeting the gut microbiota with inulin-type fructans: preclinical demonstration of a novel approach in the management of endothelial dysfunction. *Gut* doi: 10.1136/gutjnl-2016-313316 [Epub ahead of print].
- Collado, M. C., Derrien, M., Isolauri, E., de Vos, W. M., and Salminen, S. (2007). Intestinal integrity and Akkermansia muciniphila, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the elderly. *Appl. Environ. Microbiol.* 73, 7767–7770. doi: 10.1128/AEM.01477-07
- Collado, M. C., Laitinen, K., Salminen, S., and Isolauri, E. (2012). Maternal weight and excessive weight gain during pregnancy modify the immunomodulatory potential of breast milk. *Pediatr. Res.* 72, 77–85. doi: 10.1038/pr.2012.42
- Dao, M. C., Everard, A., Aron-Wisniewsky, J., Sokolovska, N., Prifti, E., Verger, E. O., et al. (2015). Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. *Gut* 65, 426–436. doi: 10.1136/gutjnl-2014-308778
- David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe, B. E., et al. (2014). Diet rapidly and reproducibly alters the human gut microbiome. *Nature* 505, 559–563. doi: 10.1038/nature12820
- de la Cuesta-Zuluaga, J., Mueller, N. T., Corrales-Agudelo, V., Velasquez-Mejia, E. P., Carmona, J. A., Abad, J. M., et al. (2017). Metformin is associated with higher relative abundance of mucin-degrading Akkermansia muciniphila and several short-chain fatty acid-producing microbiota in the gut. *Diabetes Care* 40, 54–62. doi: 10.2337/dc16-1324
- Derrien, M., Collado, M. C., Ben-Amor, K., Salminen, S., and de Vos, W. M. (2008). The Mucin degrader Akkermansia muciniphila is an abundant resident of the human intestinal tract. *Appl. Environ. Microbiol.* 74, 1646–1648. doi: 10.1128/AEM.01226-07
- Derrien, M., Van Baarlen, P., Hooiveld, G., Norin, E., Muller, M., and de Vos, W. M. (2011). Modulation of mucosal immune response, tolerance, and proliferation in mice colonized by the mucin-degrader Akkermansia muciniphila. *Front. Microbiol.* 2:166. doi: 10.3389/fmicb.2011.00166
- Derrien, M., Vaughan, E. E., Plugge, C. M., and de Vos, W. M. (2004). Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. *Int. J. Syst. Evol. Microbiol.* 54(Pt 5), 1469–1476. doi: 10.1099/ijs.0.02873-0
- Dewulf, E. M., Cani, P. D., Neyrinck, A. M., Possemiers, S., Holle, A. V., Muccioli, G. G., et al. (2011). Inulin-type fructans with prebiotic properties counteract GPR43 overexpression and PPARgamma-related adipogenesis in the white adipose tissue of high-fat diet-fed mice. *J. Nutr. Biochem.* 22, 712–722. doi: 10.1016/j.jnutbio.2010.05.009
- Douillard, F. P., and de Vos, W. M. (2014). Functional genomics of lactic acid bacteria: from food to health. *Microb. Cell Fact.* 13(Suppl. 1), S8. doi: 10.1186/1475-2859-13-S1-S8
- Dubourg, G., Lagier, J. C., Armougom, F., Robert, C., Audoly, G., Papazian, L., et al. (2013). High-level colonisation of the human gut by Verrucomicrobia following broad-spectrum antibiotic treatment. *Int. J. Antimicrob. Agents* 41, 149–155. doi: 10.1016/j.ijantimicag.2012.10.012
- Everard, A., Belzer, C., Geurts, L., Ouwerkerk, J. P., Druart, C., Bindels, L. B., et al. (2013). Cross-talk between Akkermansia muciniphila and intestinal epithelium

- controls diet-induced obesity. *Proc. Natl. Acad. Sci. U.S.A.* 110, 9066–9071. doi: 10.1073/pnas.1219451110
- Everard, A., Lazarevic, V., Derrien, M., Girard, M., Muccioli, G. M., Neyrinck, A. M., et al. (2011). Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. *Diabetes Metab. Res. Rev.* 60, 2775–2786. doi: 10.2337/db11-0227
- Everard, A., Lazarevic, V., Gaia, N., Johansson, M., Stahlman, M., Backhed, F., et al. (2014). Microbiome of prebiotic-treated mice reveals novel targets involved in host response during obesity. *ISME J.* 8, 2116–2130. doi: 10.1038/ismej.2014.45
- Forslund, K., Hildebrand, F., Nielsen, T., Falony, G., Le Chatelier, E., Sunagawa, S., et al. (2015). Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. *Nature* 528, 262–266. doi: 10.1038/nature15766
- GBD 2015 Obesity Collaborators, Afshin, A., Forouzanfar, M. H., Reitsma, M. B., Sur, P., Estep, K., et al. (2017). Health effects of overweight and obesity in 195 countries over 25 Years. *N. Engl. J. Med.* 377, 13–27. doi: 10.1056/NEJMoa1614362
- Gibson, G. R., Hutkins, R., Sanders, M. E., Prescott, S. L., Reimer, R. A., Salminen, S. J., et al. (2017). Expert consensus document: the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. *Nat. Rev. Gastroenterol. Hepatol.* 14, 510–526. doi: 10.1038/nrgastro.2017.75
- Gibson, G. R., and Roberfroid, M. B. (1995). Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. *J. Nutr.* 125, 1401–1412.
- Gomez-Gallego, C., Pohl, S., Salminen, S., De Vos, W. M., and Kneifel, W. (2016). *Akkermansia muciniphila*: a novel functional microbe with probiotic properties. *Benef. Microbes* 7, 571–584. doi: 10.3920/BM2016.0009
- Grander, C., Adolph, T. E., Wieser, V., Lowe, P., Wrzosek, L., Gyongyosi, B., et al. (2017). Recovery of ethanol-induced *Akkermansia muciniphila* depletion ameliorates alcoholic liver disease. *Gut* doi: 10.1136/gutjnl-2016-313432 [Epub ahead of print].
- Greer, R. L., Dong, X., Moraes, A. C., Zielke, R. A., Fernandes, G. R., Peremyslova, E., et al. (2016). *Akkermansia muciniphila* mediates negative effects of IFN γ on glucose metabolism. *Nat. Commun.* 7:13329. doi: 10.1038/ncomms13329
- Hartstra, A. V., Bouter, K. E., Backhed, F., and Nieuwdorp, M. (2015). Insights into the role of the microbiome in obesity and type 2 diabetes. *Diabetes Care* 38, 159–165. doi: 10.2337/dc14-0769
- Hill, C., Guarner, F., Reid, G., Gibson, G. R., Merenstein, D. J., Pot, B., et al. (2014). Expert consensus document: the international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nat. Rev. Gastroenterol. Hepatol.* 11, 506–514. doi: 10.1038/nrgastro.2014.66
- Jeurink, P. V., van Bergenhenegouwen, J., Jimenez, E., Knippels, L. M., Fernandez, L., Garssen, J., et al. (2013). Human milk: a source of more life than we imagine. *Benef. Microbes* 4, 17–30. doi: 10.3920/BM2012.0040
- Korpela, K., Flint, H. J., Johnstone, A. M., Lappi, J., Poutanen, K., Dewulf, E., et al. (2014). Gut microbiota signatures predict host and microbiota responses to dietary interventions in obese individuals. *PLoS ONE* 9:e90702. doi: 10.1371/journal.pone.0090702
- Leal-Diaz, A. M., Noriega, L. G., Torre-Villalvazo, I., Torres, N., Aleman-Escondrillas, G., Lopez-Romero, P., et al. (2016). Agamiel concentrate from *Agave salmiana* and its extracted saponins attenuated obesity and hepatic steatosis and increased *Akkermansia muciniphila* in C57BL6 mice. *Sci. Rep.* 6:34242. doi: 10.1038/srep34242
- Li, J., Lin, S., Vanhoutte, P. M., Woo, C. W., and Xu, A. (2016). *Akkermansia muciniphila* protects against atherosclerosis by preventing metabolic endotoxemia-induced inflammation in apoe $^{-/-}$ mice. *Circulation* 133, 2434–2446. doi: 10.1161/CIRCULATIONAHA.115.019645
- Li, J., Zhao, F., Wang, Y., Chen, J., Tao, J., Tian, G., et al. (2017). Gut microbiota dysbiosis contributes to the development of hypertension. *Microbiome* 5:14. doi: 10.1186/s40168-016-0222-x
- Liu, T. W., Cephas, K. D., Holscher, H. D., Kerr, K. R., Mangian, H. F., Tappenden, K. A., et al. (2016). Nondigestible fructans alter gastrointestinal barrier function, gene expression, histomorphology, and the microbiota profiles of diet-induced obese C57BL/6J mice. *J. Nutr.* 146, 949–956. doi: 10.3945/jn.115.227504
- Marchesi, J. R., Adams, D. H., Fava, F., Hermes, G. D., Hirschfield, G. M., Hold, G., et al. (2016). The gut microbiota and host health: a new clinical frontier. *Gut* 65, 330–339. doi: 10.1136/gutjnl-2015-309990
- Maurer, A. D., Eller, L. K., Hallam, M. C., Taylor, K., and Reimer, R. A. (2010). Consumption of diets high in prebiotic fiber or protein during growth influences the response to a high fat and sucrose diet in adulthood in rats. *Nutr. Metab. (Lond)* 7:77. doi: 10.1186/1743-7075-7-77
- Ojo, B., El-Rassi, G. D., Payton, M. E., Perkins-Veazie, P., Clarke, S., Smith, B. J., et al. (2016). Mango supplementation modulates gut microbial dysbiosis and short-chain fatty acid production independent of body weight reduction in C57BL/6 mice fed a high-fat diet. *J. Nutr.* 146, 1483–1491. doi: 10.3945/jn.115.226688
- Ottman, N., Huuskonen, L., Reunanen, J., Boeren, S., Klievink, J., Smidt, H., et al. (2016). Characterization of outer membrane proteome of *Akkermansia muciniphila* reveals sets of novel proteins exposed to the human intestine. *Front. Microbiol.* 7:1157. doi: 10.3389/fmicb.2016.01157
- Ottman, N., Reunanen, J., Meijerink, M., Pietila, T. E., Kainulainen, V., Klievink, J., et al. (2017). Pili-like proteins of *Akkermansia muciniphila* modulate host immune responses and gut barrier function. *PLoS ONE* 12:e0173004. doi: 10.1371/journal.pone.0173004
- Ouwehand, A. C., Derrien, M., de Vos, W., Tiihonen, K., and Rautonen, N. (2005). Prebiotics and other microbial substrates for gut functionality. *Curr. Opin. Biotechnol.* 16, 212–217. doi: 10.1016/j.copbio.2005.01.007
- Ouwerkerk, J. P., van der Ark, K. C., Davids, M., Claassens, N. J., Robert Finestra, T., de Vos, W. M., et al. (2016). Adaptation of *Akkermansia muciniphila* to the oxic-anoxic interface of the mucus layer. *Appl. Environ. Microbiol.* doi: 10.1128/AEM.01641-16 [Epub ahead of print].
- Pachikian, B. D., Essaghir, A., Demoulin, J. B., Catry, E., Neyrinck, A. M., Dewulf, E. M., et al. (2012). Prebiotic approach alleviates hepatic steatosis: implication of fatty acid oxidative and cholesterol synthesis pathways. *Mol. Nutr. Food Res.* 57, 347–359. doi: 10.1002/mnfr.201200364
- Plovier, H., Everard, A., Druart, C., Depommier, C., Van Hul, M., Geurts, L., et al. (2017). A purified membrane protein from *Akkermansia muciniphila* or the pasteurized bacterium improves metabolism in obese and diabetic mice. *Nat. Med.* 23, 107–113. doi: 10.1038/nm.4236
- Png, C. W., Linden, S. K., Gilshenan, K. S., Zoetendal, E. G., McSweeney, C. S., Sly, L. I., et al. (2010). Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. *Am. J. Gastroenterol.* 105, 2420–2428. doi: 10.1038/ajg.2010.281
- Reid, D. T., Eller, L. K., Nettleton, J. E., and Reimer, R. A. (2016). Postnatal prebiotic fibre intake mitigates some detrimental metabolic outcomes of early overnutrition in rats. *Eur. J. Nutr.* 55, 2399–2409. doi: 10.1007/s00394-015-1047-2
- Roberfroid, M., Gibson, G. R., Hoyles, L., McCartney, A. L., Rastall, R., Rowland, I., et al. (2010). Prebiotic effects: metabolic and health benefits. *Br. J. Nutr.* 104, S1–S63. doi: 10.1017/S0007114510003363
- Salonen, A., Lahti, L., Salojarvi, J., Holtrop, G., Korpela, K., Duncan, S. H., et al. (2014). Impact of diet and individual variation on intestinal microbiota composition and fermentation products in obese men. *ISME J.* 8, 2218–2230. doi: 10.1038/ismej.2014.63
- Schneeberger, M., Everard, A., Gomez-Valades, A. G., Matamoros, S., Ramirez, S., Delzenne, N. M., et al. (2015). *Akkermansia muciniphila* inversely correlates with the onset of inflammation, altered adipose tissue metabolism and metabolic disorders during obesity in mice. *Sci. Rep.* 5:16643. doi: 10.1038/srep16643
- Seregin, S. S., Golovchenko, N., Schaf, B., Chen, J., Pudlo, N. A., Mitchell, J., et al. (2017). NLRP6 protects Il10 $^{-/-}$ mice from colitis by limiting colonization of *Akkermansia muciniphila*. *Cell Rep.* 19, 733–745. doi: 10.1016/j.celrep.2017.03.080
- Shen, J., Tong, X., Sud, N., Khound, R., Song, Y., Maldonado-Gomez, M. X., et al. (2016). Low-density lipoprotein receptor signaling mediates the triglyceride-lowering action of *Akkermansia muciniphila* in genetic-induced hyperlipidemia. *Arterioscler. Thromb. Vasc. Biol.* 36, 1448–1456. doi: 10.1161/ATVBAHA.116.307597

- 799 Shetty, S. A., Hugenholtz, F., Lahti, L., Smidt, H., and de Vos, W. M. (2017).
800 Intestinal microbiome landscaping: insight in community assemblage and
801 implications for microbial modulation strategies. *FEMS Microbiol. Rev.* 41,
802 182–199. doi: 10.1093/femsre/fuw045
- 803 Shin, N. R., Lee, J. C., Lee, H. Y., Kim, M. S., Whon, T. W., Lee, M. S., et al.
804 (2014). An increase in the *Akkermansia* spp. population induced by metformin
805 treatment improves glucose homeostasis in diet-induced obese mice. *Gut* 63,
806 727–735. doi: 10.1136/gutjnl-2012-303839
- 807 Singh, D. P., Singh, J., Boparai, R. K., Zhu, J., Mantri, S., Khare, P., et al.
808 (2017). Isomalto-oligosaccharides, a prebiotic, functionally augment green tea
809 effects against high fat diet-induced metabolic alterations via preventing gut
810 dysbiosis in mice. *Pharmacol. Res.* 123, 103–113. doi: 10.1016/j.phrs.2017.
811 06.015
- 812 Song, H., Chu, Q., Yan, F., Yang, Y., Han, W., and Zheng, X. (2016). Red
813 pitaya betacyanins protects from diet-induced obesity, liver steatosis and
814 insulin resistance in association with modulation of gut microbiota in mice.
815 *J. Gastroenterol. Hepatol.* 31, 1462–1469. doi: 10.1111/jgh.13278
- 816 Thaïss, C. A., Levy, M., Korem, T., Dohnalova, L., Shapiro, H., Jaitin,
817 D. A., et al. (2016). Microbiota diurnal rhythmicity programs host
818 transcriptome oscillations. *Cell* 167, 1495–1510.e12. doi: 10.1016/j.cell.2016.
819 11.003
- 820 Ward, T. L., Hosid, S., Ioshikhes, I., and Altosaar, I. (2013). Human
821 milk metagenome: a functional capacity analysis. *BMC Microbiol.* 13:116.
822 doi: 10.1186/1471-2180-13-116
- 823 Wen, L., and Duffy, A. (2017). Factors influencing the gut microbiota,
824 inflammation, and type 2 diabetes. *J. Nutr.* 147, 1468S–1475S. doi: 10.3945/jn.
825 116.240754
- 826 Yassour, M., Lim, M. Y., Yun, H. S., Tickle, T. L., Sung, J., Song, Y. M., et al.
827 (2016). Sub-clinical detection of gut microbial biomarkers of obesity and type 2
828 diabetes. *Genome Med.* 8:17. doi: 10.1186/s13073-016-0271-6
- 829 Zeevi, D., Korem, T., Zmora, N., Israeli, D., Rothschild, D., Weinberger, A., et al.
830 (2015). Personalized nutrition by prediction of glycemic responses. *Cell* 163,
831 1079–1094. doi: 10.1016/j.cell.2015.11.001
- 832 Zhang, X., Shen, D., Fang, Z., Jie, Z., Qiu, X., Zhang, C., et al. (2013). Human gut
833 microbiota changes reveal the progression of glucose intolerance. *PLoS ONE*
834 8:e71108. doi: 10.1371/journal.pone.0071108
- 835 Zhu, L., Qin, S., Zhai, S., Gao, Y., and Li, L. (2017). Inulin with different degrees of
836 polymerization modulates composition of intestinal microbiota in mice. *FEMS*
837 *Microbiol. Lett.* 364:fnx075. doi: 10.1093/femsle/fnx075
- 838 **Conflict of Interest Statement:** PC and WdV are inventors on patent applications
839 dealing with the use of *A. muciniphila* and its components in the treatment of
840 obesity and related disorders.
- 841 The authors declare that the research was conducted in the absence of any
842 commercial or financial relationships that could be construed as a potential conflict
843 of interest.
- 844 Copyright © 2017 Cani and de Vos. This is an open-access article distributed
845 under the terms of the Creative Commons Attribution License (CC BY). The use,
846 distribution or reproduction in other forums is permitted, provided the original
847 author(s) or licensor are credited and that the original publication in this journal
848 is cited, in accordance with accepted academic practice. No use, distribution or
849 reproduction is permitted which does not comply with these terms.